Receive The Newest Study Notifications

The Collaboration will be led by Renowned Cell and Gene Therapy Experts Dr. John DiPersio and Dr. Mark Schroeder with Advisory support to Cellect by Prof. Negrin of Stanford and Dr. Cutler of Harvard Medical School Cellect Biotechnology Ltd. (Nasdaq: APOP), a...

Antibody against Chikungunya virus (mRNA-1944) is the first development candidate from Moderna’s systemic therapeutics modalities to start human dosing Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics...

Exicure, Inc. (OTCQB: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced four of the clinical trial sites for the Company’s Phase 1b/2 trial of AST-008. “Exicure is thrilled to announce...

PSALA, SWEDEN - LIDDS AB (publ) has received approval from the Danish Medicines Agency (DKMA) to conduct its Phase I NZ-DTX-001 clinical trial. The Danish study is in addition to the Phase I NZ-DTX-001 clinical trial being conducted at the Karolinska University...

Dr. Valerie Williams of St. Elizabeth Healthcare is involved in a national groundbreaking clinical trial for patients with gastroesophageal reflux disease (GERD). Dr. Williams is the fourth author listed in the CALIBER Study, published in the January 2019 issue of...

VLP Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for a clinical trial of the Company's VLPM01 malaria vaccine. The Phase I/IIa clinical trial will begin recruiting participants...

Newron Pharmaceuticals S.p.A.(“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced the successful completion of patient enrollment in...

First patient enrolled in StimLabs Revita Efficacy Trial for Diabetic Foot Ulcers StimLabs, a leader in regenerative technologies and products that are revolutionizing patient care, today announced that the first patient has been enrolled in the company's clinical...

Sylentis a PharmaMar Group company (MSE:PHM), has announced today the results of the HELIX [i]exploratory clinical trial; a Phase 3 efficacy and safety study with tivanisiran compared against artificial tears for the treatment of dry eye disease[ii]. Tivanisiran has...

Hua Medicine (“Hua” or “the Company”; Stock Code: 2552.HK) a Shanghai-based drug development company focused on developing a global first-in-class oral drug for the treatment of Type 2 diabetes (T2D), announced today dosing of the first patient in a clinical trial of...

Successful interim results in the 700 mg monotherapy arm prompted the FDA to allow CytoDyn to switch all remaining combination therapy patients from CD02-Extension study from 350 mg to 700 mg dose.  CytoDyn is in negotiations for post-approval sales distribution...

Real-world evidence (RWE) or real-world data (RWD) relates to the collection of information about a drug’s safety and efficacy outside the structure of a clinical trial. Speaking yesterday at the Bipartisan Policy Center conference, U.S. Food and Drug Administration...

CD8+ T Cell agent could be used for early prediction of therapeutic response in metastatic cancer patients ImaginAb Inc. announced the enrollment of the first patient in the Phase II clinical trial of the company’s CD8+ T Cell imaging agent. The trial will enroll...

80% of Treated Patients with Clinical Response at 48 weeks, Published in Gastroenterology Cytori Therapeutics, Inc. (NASDAQ: CYTX) announces the publication of results from a pilot investigator-initiated clinical trial of Cytori Cell Therapy™ for the treatment of...

The Phase 1 clinical trial evaluating SPR720 is a double-blind, placebo-controlled, ascending dose, multi-cohort study in healthy subjects consisting of single ascending dose and multiple ascending dose cohorts. Spero Therapeutics,  a multi-asset clinical-stage...

DrugCendR Inc., a clinical-stage biopharmaceutical company dedicated to developing next generation cancer therapies designed to overcome the barriers of drug delivery in solid tumors, reported today positive progress with its ongoing pancreatic cancer clinical trial....

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced updates on its clinical program for its lead investigational treatment, DPX-Survivac, as a potential monotherapy in advanced recurrent ovarian cancer. In December 2018, IMV...

The Alzheimer's Prevention Initiative (API) study of crenezumab in familial Alzheimer's disease continues Roche remains committed to ongoing clinical studies in Alzheimer's disease, including GRADUATE Phase III trials with gantenerumab and the TAURIEL Phase II...

Dr. Jacob Unger at Maxwell Aesthetics in Nashville, TN, is an investigator enrolling patients for an FDA-reviewed trial exploring Motiva Implants® The U.S. Food and Drug Administration oversees the investigation and approval not only of medicines, but also devices...

4G Clinical, a cutting-edge randomization and trial supply management (RTSM) provider, today announced a strategic partnership with EPS Corporation, one of the largest CROs in Japan. "We are very excited to select 4G Clinical as our IRT/RTSM provider for multinational...